Voyager Therapeutics (NASDAQ:VYGR) had its price target trimmed by Wedbush from $34.00 to $27.00 in a research note published on Wednesday morning, The Fly reports. The brokerage currently has an outperform rating on the stock. Wedbush also issued estimates for Voyager Therapeutics Q2 2020 earnings at ($0.83) EPS, FY2020 earnings at ($3.18) EPS, Q1 2021 earnings at ($0.81) EPS, Q2 2021 earnings at ($0.79) EPS, Q3 2021 earnings at ($0.71) EPS, Q4 2021 earnings at ($0.69) EPS, FY2021 earnings at ($2.99) EPS, FY2022 earnings at ($2.76) EPS, FY2023 earnings at ($2.24) EPS and FY2024 earnings at $0.29 EPS.

Several other brokerages have also issued reports on VYGR. ValuEngine raised shares of Voyager Therapeutics from a sell rating to a hold rating in a research note on Tuesday, February 25th. Zacks Investment Research lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a research note on Saturday, January 25th. Oppenheimer began coverage on shares of Voyager Therapeutics in a research note on Wednesday, February 5th. They set an outperform rating and a $26.00 target price on the stock. BidaskClub raised shares of Voyager Therapeutics from a strong sell rating to a sell rating in a research note on Wednesday, February 5th. Finally, Evercore ISI reissued a hold rating and set a $18.00 target price on shares of Voyager Therapeutics in a research note on Sunday, November 24th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. Voyager Therapeutics has a consensus rating of Hold and a consensus price target of $22.38.

NASDAQ:VYGR opened at $10.97 on Wednesday. The firms fifty day moving average is $12.34 and its 200-day moving average is $14.70. Voyager Therapeutics has a 52 week low of $10.13 and a 52 week high of $28.79.

In other Voyager Therapeutics news, COO Matthew P. Ottmer sold 3,724 shares of the companys stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.36, for a total transaction of $49,752.64. Following the transaction, the chief operating officer now owns 26,276 shares in the company, valued at $351,047.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andre Turenne sold 10,705 shares of the companys stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.36, for a total transaction of $143,018.80. Following the transaction, the chief executive officer now owns 85,545 shares in the company, valued at approximately $1,142,881.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,557 shares of company stock worth $234,562. 33.60% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC raised its holdings in Voyager Therapeutics by 335.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,350 shares of the companys stock worth $60,000 after buying an additional 3,350 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Voyager Therapeutics by 46.0% during the fourth quarter. Victory Capital Management Inc. now owns 6,199 shares of the companys stock worth $86,000 after buying an additional 1,954 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Voyager Therapeutics during the third quarter worth $139,000. AJO LP acquired a new position in Voyager Therapeutics during the fourth quarter worth $118,000. Finally, Jackson Wealth Management LLC acquired a new position in Voyager Therapeutics during the fourth quarter worth $120,000. Hedge funds and other institutional investors own 85.69% of the companys stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Recommended Story: What is meant by buying and selling pressure?

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Wedbush Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $27.00 - Redmond Register

Comments are closed.